In this study, we analyzed the effects of RAS inhibitors and SGLT2 inhibitors alone or in combination on ESKD in people with both diabetes and hypertension using a large-scale population dataset from the National Health Information Database (NHID). Here, SLC5A2 is linked to hypertensive disorder.